<DOC>
	<DOCNO>NCT00950612</DOCNO>
	<brief_summary>This observer blind study assess safety immunogenicity GSK Biologicals ' investigational 692342 vaccine administer 0 , 1 month healthy adolescent live TB-endemic region .</brief_summary>
	<brief_title>Safety Immunogenicity Candidate Tuberculosis ( TB ) Vaccine Healthy HIV Negative Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parent ( ) / legal guardian ( ) comply requirement protocol . A male female , include , 13 17 year age time first vaccination . Written inform consent obtain subject 's parent ( ) legal guardian ( ) . Written inform assent obtain subject . Free obvious health problem establish medical history clinical examination enter study . Seronegative HIV1 . No history TB disease . No active pulmonary disease chest Xray . Availability duration immunisation followup period , family planning move away study area within next year . Female subject nonchildbearing potential may enrol study . Female subject childbearing potential may enrol study , subject abstinent , practice adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire vaccination period 2 month completion vaccination series . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine , plan use study period . Administration register live vaccine foreseen study within 30 day precede first dose study vaccine administration register inactivated vaccine within 14 day precede first dose study vaccine . History previous administration investigational Mycobacterium tuberculosis vaccine . History previous exposure component investigational vaccine . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first vaccine dose . Any condition illness ( acute , chronic history ) medication , opinion investigator might interfere evaluation safety immunogenicity study vaccine . Administration immunoglobulins and/or blood product within three month precede first dose vaccine , plan administration study . Planned participation participation another experimental clinical study study period . A family history congenital hereditary immunodeficiency . Any chronic drug therapy continue study period , exception vitamin and/or dietary supplement , birth control pill , antihistamine seasonal allergy Specific Serotonin Reuptake Inhibitors ( SSRIs ) . History allergic reaction ( significant IgEmediated event ) anaphylaxis vaccine . History allergic disease reaction likely exacerbate component study vaccine . Pregnant female , lactate female female planning become pregnant discontinue contraceptive precaution . Drug and/or alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Tuberculosis vaccine</keyword>
</DOC>